01-09-2000 | ORIGINAL ARTICLE
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group
Published in: Annals of Hematology | Issue 9/2000
Login to get access